UK regulators who are funded by Bill Gates have granted approval to a recently developed and untested COVID vaccine, financed by Bill Gates, which seems to have been specifically intended for deployment in developing nations.
The SKYCovion vaccine was awarded regulatory approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) despite the lack of testing. MHRA is primarily funded by the the Bill & Melinda Gates Foundation. SKYCovion, developed in South Korea, received substantial funding from Bill Gates.
It incorporates a section of the SARS-CoV-2 virus spike protein along with an “adjuvant.” This new, untested vaccine consists of self-assembled nanoparticles and is enhanced with GSK’s AS03 adjuvant technology.
Factual
248
Questionable
0
Manufactured (By SK Bioscience Co., Ltd. Collaboration with the International Vaccine Institute, GlaxoSmithKline and Coalition for Epidemic Preparedness Innovations), and approved for use in S.Korea. (Link #1 and Link #2)
Says Status is Active but Not Yet Recruiting. Did not specify how many participants from each country but there have been 2 trials made here already. (Link #3)
Results according to GSK: “SK bioscience conducted a Phase III clinical trial in 4,037 adults over 18-year-old across 6 countries (Thailand, Vietnam, New Zealand, Ukraine, the Philippines and South Korea). The vaccine candidate demonstrated superior neutralizing antibody titres over AstraZeneca’s Vaxzevria™ (control vaccine), a currently authorized COVID-19 vaccine. SKYCovione™ vaccine candidate showed a clinically favorable safety profile. …
The results of the Phase III clinical trial show a superior neutralizing antibody response of SKYCovione™ against SARS-CoV-2 parental strain, 2.93 times that of a control vaccine 2 weeks after the second dose.” (link #3)
According to Korea Biomedical Review last Oct.2022 (Independent): (Link #4)
– “Although SK Bioscience argues that the speed of inoculation is getting faster, industry watchers say the company is fighting an uphill battle.”
– No WHO EUL approval yet.
출처 : KBR(https://www.koreabiomed.com)
Any Gain-Of-Function research though? Hmmm … Ukraine + New Zealand + Taiwan + Vietnam … Please, not in my country.
https://clinicaltrials.gov/ct2/show/results/NCT05007951
https://www.gsk.com/en-gb/media/press-releases/sk-bioscience-and-gsk-s-adjuvanted-covid-19-vaccine-candidate-meets-coprimary-objectives-in-a-phase-iii-study/
https://www.koreabiomed.com/news/articleView.html?idxno=14753